NEW YORK (GenomeWeb News) – A Canadian non-profit research center focused on preventing organ failure has licensed a database from the Indian drug discovery research firm GVK Biosciences for studies of biomarker development for heart, lung, and kidney failure.
Under the agreement, the Prevention of Organ Failure Centre (PROOF Centre) at the University of British Columbia will use the GVK Bio Online Clinical Biomarker Database (GOBIOM) to assess the commercialization potential of the PROOF Centre's biomarkers, GVK Bio said today.
The GOBIOM database contains 14,000 biomarkers, including genomic, biochemical, imaging, metabolite, cellular, and other markers, and data points from experimental, analytical, clinical, and statistical data with their qualifications under different medical interventions. The database includes information from more than 100 different ethnicities and it links biomarkers to drug and therapeutic areas, and targets, and includes toxicity and adverse events data.
“Heart, lung and kidney diseases are a tremendous cost to society – in dollars and lives," PROOF Centre Director Bruce McManus said in a statement. "Our mission … is to create new tools that will help alleviate this global burden. Integrating knowledge from GVK Biosciences’ Biomarker Database will be a significant advantage in helping us accelerate the transfer of these new tests into the clinic—ensuring patients will benefit faster.”
Financial terms of the agreement were not released.